| Basics |
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
|
| IPO Date: |
May 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$2.84B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 2.00%
|
| Avg Daily Range (30 D): |
$0.54 | 1.13%
|
| Avg Daily Range (90 D): |
$0.54 | 1.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.56M |
| Avg Daily Volume (90 D): |
.64M |
| Trade Size |
| Avg Trade Size (Sh.): |
89 |
| Avg Trade Size (Sh.) (30 D): |
48 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Inst.Trades: |
4,416 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$3.75M |
| Avg Inst. Trade (90 D): |
$2.85M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.05M |
| Avg Closing Trade (30 D): |
$5.81M |
| Avg Closing Trade (90 D): |
$4.8M |
| Avg Closing Volume: |
65.24K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$1.17
|
$.4
|
$-.21
|
|
Diluted EPS
|
$1.15
|
$.4
|
$-.21
|
|
Revenue
|
$ 665.13M
|
$ 165.45M
|
$ 149.82M
|
|
Gross Profit
|
$ 588.85M
|
$ 148.63M
|
$ 134.06M
|
|
Net Income / Loss
|
$ 64.5M
|
$ 22.5M
|
$ -11.83M
|
|
Operating Income / Loss
|
$ 64.14M
|
$ 12.14M
|
$ -10.26M
|
|
Cost of Revenue
|
$ 76.27M
|
$ 16.83M
|
$ 15.76M
|
|
Net Cash Flow
|
$ 92.62M
|
$ 28.86M
|
$ 46.52M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
